🇺🇸 FDA
Patent

US 7560437

Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase

granted A61KA61K38/00A61K38/43

Quick answer

US patent 7560437 (Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase) held by The Regents of the University of Colorado expires Mon Jul 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado
Grant date
Tue Jul 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K38/00, A61K38/43, A61K39/00, A61K48/00